Research advances of modern and traditional medicine on dry age-related macular degeneration
10.3980/j.issn.1672-5123.2022.5.21
- VernacularTitle:干性年龄相关性黄斑变性现代医药与中医药研究新进展
- Author:
Lu Xing
1
Author Information
1. <sup>1</sup>Shaanxi Key Laboratory of Ischemic Cardiovascular Disease;Xi'an Key Laboratory of Basic and Translation of Cardiovascular Diabetic Disease;Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an 710021, Shaanxi Province, China|<sup>2</sup>School of Pharmacy, Shaanxi University of Traditional Chinese Medicine, Xianyang 712046, Shaanxi Province, China|<sup>3</sup>School of Life Sciences, Northwest University, Xi'an 710069, Shaanxi Province, China|<sup>4</sup>Department of Ophthalmology, the First Affiliated Hospital of Xi'an Medical University, Xi'an 710077, Shaanxi Province, China
- Publication Type:Journal Article
- Keywords:
age-related macular degeneration;
dry;
geographic atrophy;
drusen;
new drugs;
complement inhibitor;
stem cell transplantation;
traditional Chinese medicine
- From:
International Eye Science
2022;22(5):803-808
- CountryChina
- Language:Chinese
-
Abstract:
Age-related macular degeneration(ARMD)is one of the main causes of irreversible visual impairment in the middle-aged and elderly people, which severely impacts the patient's life quality and poses a substantial health economic burden on society. There are two types of late ARMD in clinic: wet ARMD and dry ARMD. Anti-vascular endothelial growth factor drugs, as first-line clinical drugs for wet ARMD, achieved remarkable efficacy. For dry ARMD, however, effective therapies are in the air. This review focuses on the potential drugs, biological therapies and traditional Chinese medicines that made significant progresses in clinical trials for dry ARMD, including anti-inflammatory drugs(doxycycline and FHTR2163), anti-oxidants(risuteganib and elamipretide), complement inhibitors(APL-2 and zimura), visual cycle modulators(ALK-001), neuroprotective agents(brimonidine), stem cell transplantation(MA09-hRPE and BMMF), gene therapy(HMR59), and traditional Chinese medicine(saffron, curcumin, quercetin and resveratrol). The new drugs exhibited favorable clinical efficacy and broad application prospects, which would foster hope for improvement and treatment of ARMD.
- Full text:202205021.pdf
